Tumor-derived fibulin-3 activates pro-invasive NF-κB signaling in glioblastoma cells and their microenvironment

Oncogene

Volumn 36, Issue 34, 2017, Pages 4875-4886

  Nandhu, M S ^a,b   Kwiatkowska, A ^a   Bhaskaran, V ^a   Hayes, J ^c   Hu, B ^d,e   Viapiano, M S ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; FIBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR MARKER; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; BRAIN TUMOR; CELL PROLIFERATION; DISEASE COURSE; GLIOBLASTOMA; GLIOMA; HUMAN; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION; TUMOR MICROENVIRONMENT;

ADAM17 PROTEIN; ANIMALS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; MICE, NUDE; NEOPLASM INVASIVENESS; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85017505919     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.109     Document Type: Article

References (66)

1. Zong H, Verhaak RG, Canoll P. The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev Mol Diagn 2012; 12: 383–394. DOI: 10.1586/erm.12.30
2. Watkins S, Sontheimer H. Unique biology of gliomas: challenges and opportunities. Trends Neurosci 2012; 35: 546–556. DOI: 10.1016/j.tins.2012.05.001
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492–507. DOI: 10.1056/NEJMra0708126
4. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014; 16 (Suppl 4): iv1–63. DOI: 10.1093/neuonc/nou223
5. Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 2012; 149: 36–47. DOI: 10.1016/j.cell.2012.03.009
6. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR et al. The somatic genomic landscape of glioblastoma. Cell 2013; 155: 462–477. DOI: 10.1016/j.cell.2013.09.034
7. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98–110. DOI: 10.1016/j.ccr.2009.12.020
8. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010; 463: 318–325. DOI: 10.1038/nature08712
9. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol 2011; 12: 695–708. DOI: 10.1038/ni.2065
10. Korkolopoulou P, Levidou G, Saetta AA, El-Habr E, Eftichiadis C, Demenagas P et al. Expression of nuclear factor-κB in human astrocytomas: relation to pI κBa, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol 2008; 39: 1143–1152. DOI: 10.1016/j.humpath.2008.01.020
11. Puliyappadamba VT, Hatanpaa KJ, Chakraborty S, Habib AA. The role of NF-κB in the pathogenesis of glioma. Mol Cell Oncol 2014; 1: e963478. DOI: 10.4161/23723548.2014.963478
12. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 2013; 24: 331–346. DOI: 10.1016/j.ccr.2013.08.001
13. Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN. Analysis of the activation status of Akt, NF-κB, and Stat3 in human diffuse gliomas. Lab Invest 2004; 84: 941–951. DOI: 10.1038/labinvest.3700123
14. Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H et al. in vitro and in vivo activity of the nuclear factor-κB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 2004; 10: 5595–5603. DOI: 10.1158/1078-0432.CCR-03-0392
15. Kusne Y, Carrera-Silva EA, Perry AS, Rushing EJ, Mandell EK, Dietrich JD et al. Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFalpha in glioblastoma. Science signaling 2014; 7: ra75. DOI: 10.1126/scisignal.2005196
16. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS. Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion. Mol Cancer Res 2009; 7: 1756–1770. DOI: 10.1158/1541-7786.MCR-09-0207
17. Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE et al. Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res 2012; 72: 3873–3885. DOI: 10.1158/0008-5472.CAN-12-1060
18. Nandhu MS, Hu B, Cole SE, Erdreich-Epstein A, Rodriguez-Gil DJ, Viapiano MS. Novel paracrine modulation of Notch-DLL4 signaling by fibulin-3 promotes angiogenesis in high-grade gliomas. Cancer Res 2014; 74: 5435–5448. DOI: 10.1158/0008-5472.CAN-14-0685
19. Hiddingh L, Tannous BA, Teng J, Tops B, Jeuken J, Hulleman E et al. EFEMP1 induces gamma-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget 2014; 5: 363–374. DOI: 10.18632/oncotarget.1620
20. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004; 64: 920–927. DOI: 10.1158/0008-5472.CAN-03-2073
21. Ohnishi T, Matsumura H, Izumoto S, Hiraga S, Hayakawa T. A novel model of glioma cell invasion using organotypic brain slice culture. Cancer Res 1998; 58: 2935–2940.
22. Natarajan K, Singh S, Burke TR Jr., Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB. Proc Natl Acad Sci USA 1996; 93: 9090–9095. DOI: 10.1073/pnas.93.17.9090
23. Alcamo E, Mizgerd JP, Horwitz BH, Bronson R, Beg AA, Scott M et al. Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-κB in leukocyte recruitment. J Immunol 2001; 167: 1592–1600. DOI: 10.4049/jimmunol.167.3.1592
24. Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J et al. The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18: 268–281. DOI: 10.1016/j.ccr.2010.08.006
25. Mathis BJ, Lai Y, Qu C, Janicki JS, Cui T. CYLD-mediated signaling and diseases. Curr Drug Targets 2015; 16: 284–294. DOI: 10.2174/1389450115666141024152421
26. Bozkulak EC, Weinmaster G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol 2009; 29: 5679–5695. DOI: 10.1128/MCB.00406-09
27. Rose-John S. ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res 2013; 71: 19–22. DOI: 10.1016/j.phrs.2013.01.012
28. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435: 39–44. DOI: 10.1016/S0014-5793(98)01031-X
29. Klenotic PA, Munier FL, Marmorstein LY, nand-Apte B. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem 2004; 279: 30469–30473. DOI: 10.1074/jbc.M403026200
30. Baltimore D. NF-κB is 25. Nat Immunol 2011; 12: 683–685. DOI: 10.1038/ni.2072
31. DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev 2012; 246: 379–400. DOI: 10.1111/j.1600-065X.2012.01099.x
32. Gray GK, McFarland BC, Nozell SE, Benveniste EN. NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age. Expert Rev Neurother 2014; 14: 1293–1306. DOI: 10.1586/14737175.2014.964211
33. Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NF-κB pathway: a therapeutic target in glioblastoma. Oncotarget 2011; 2: 646–653. DOI: 10.18632/oncotarget.322
34. Westhoff MA, Zhou S, Nonnenmacher L, Karpel-Massler G, Jennewein C, Schneider M et al. Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma. Mol Cancer Res 2013; 11: 1611–1623. DOI: 10.1158/1541-7786.MCR-13-0435-T
35. Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P et al. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene 2012; 31: 4054–4066. DOI: 10.1038/onc.2011.563
36. Kim JK, Jin X, Sohn YW, Jin X, Jeon HY, Kim EJ et al. Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling. Cancer Lett 2014; 353: 194–200. DOI: 10.1016/j.canlet.2014.07.034
37. Ellert-Miklaszewska A, Dabrowski M, Lipko M, Sliwa M, Maleszewska M, Kaminska B. Molecular definition of the pro-tumorigenic phenotype of glioma-activated microglia. Glia 2013; 61: 1178–1190. DOI: 10.1002/glia.22510
38. Kim YJ, Hwang SY, Han IO. Insoluble matrix components of glioma cells suppress LPS-mediated iNOS/NO induction in microglia. Biochem Biophys Res Commun 2006; 347: 731–738. DOI: 10.1016/j.bbrc.2006.06.149
39. Conti A, Guli C, La Torre D, Tomasello C, Angileri FF, Aguennouz M. Role of inflammation and oxidative stress mediators in gliomas. Cancers (Basel) 2010; 2: 693–712. DOI: 10.3390/cancers2020693
40. Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP et al. NFKBIA deletion in glioblastomas. N Engl J Med 2011; 364: 627–637. DOI: 10.1056/NEJMoa1006312
41. Kobayashi N, Kostka G, Garbe JH, Keene DR, Bachinger HP, Hanisch FG et al. A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. J Biol Chem 2007; 282: 11805–11816. DOI: 10.1074/jbc.M611029200
42. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: physiological and disease perspectives. EMBO Rep 2003; 4: 1127–1131. DOI: 10.1038/sj.embor.7400033
43. de Vega S, Iwamoto T, Yamada Y. Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 2009; 66: 1890–1902. DOI: 10.1007/s00018-009-8632-6
44. Obaya AJ, Rua S, Moncada-Pazos A, Cal S. The dual role of fibulins in tumorigenesis. Cancer Lett 2012; 325: 132–138. DOI: 10.1016/j.canlet.2012.06.019
45. Seeliger H, Camaj P, Ischenko I, Kleespies A, De Toni EN, Thieme SE et al. EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 2009; 7: 189–198. DOI: 10.1158/1541-7786.MCR-08-0132
46. En-lin S, Sheng-guo C, Hua-qiao W. The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis. Gynecol Oncol 2010; 117: 417–422. DOI: 10.1016/j.ygyno.2009.12.016
47. Song EL, Hou YP, Yu SP, Chen SG, Huang JT, Luo T et al. EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo. Gynecol Oncol 2011; 121: 174–180. DOI: 10.1016/j.ygyno.2010.11.004
48. Hwang CF, Chien CY, Huang SC, Yin YF, Huang CC, Fang FM et al. Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol 2010; 222: 367–379. DOI: 10.1002/path.2776
49. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367: 1417–1427. DOI: 10.1056/NEJMoa1115050
50. Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax 2014; 69: 895–902. DOI: 10.1136/thoraxjnl-2014-205205
51. Chen J, Wei D, Zhao Y, Liu X, Zhang J. Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinoma. PLoS One 2013; 8: e78783. DOI: 10.1371/journal.pone.0078783
52. Camaj P, Seeliger H, Ischenko I, Krebs S, Blum H, De Toni EN et al. EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem 2009; 390: 1293–1302. DOI: 10.1515/BC.2009.140
53. Hu Y, Gao H, Vo C, Ke C, Pan F, Yu L et al. Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis. Oncoscience 2014; 1: 205–215. DOI: 10.18632/oncoscience.24
54. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 2010; 45: 146–169. DOI: 10.3109/10409231003628015
55. Newton RC, Solomon KA, Covington MB, Decicco CP, Haley PJ, Friedman SM et al. Biology of TACE inhibition. Ann Rheum Dis 2001; 60 (Suppl 3): iii25–iii32.
56. Chen X, Chen L, Chen J, Hu W, Gao H, Xie B et al. ADAM17 promotes U87 glioblastoma stem cell migration and invasion. Brain Res 2013; 1538: 151–158. DOI: 10.1016/j.brainres.2013.02.025
57. Chen X, Chen L, Zhang R, Yi Y, Ma Y, Yan K et al. ADAM17 regulates self-renewal and differentiation of U87 glioblastoma stem cells. Neurosci Lett 2013; 537: 44–49. DOI: 10.1016/j.neulet.2013.01.021
58. Wolpert F, Tritschler I, Steinle A, Weller M, Eisele G. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro Oncol 2014; 16: 382–391. DOI: 10.1093/neuonc/not232
59. Zheng X, Jiang F, Katakowski M, Lu Y, Chopp M. ADAM17 promotes glioma cell malignant phenotype. Mol Carcinog 2012; 51: 150–164. DOI: 10.1002/mc.20772
60. Giltay R, Timpl R, Kostka G. Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4. Matrix Biol 1999; 18: 469–480. DOI: 10.1016/S0945-053X(99)00038-4
61. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996; 274: 787–789. DOI: 10.1126/science.274.5288.787
62. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016; 164: 550–563. DOI: 10.1016/j.cell.2015.12.028
63. Celiku O, Johnson S, Zhao S, Camphausen K, Shankavaram U. Visualizing molecular profiles of glioblastoma with GBM-BioDP. PLoS ONE 2014; 9: e101239. DOI: 10.1371/journal.pone.0101239
64. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18: 6853–6866. DOI: 10.1038/sj.onc.1203239
65. Shelest E, Kel AE, Goessling E, Wingender E. Prediction of potential C/EBP/NF-κB composite elements using matrix-based search methods. In Silico Biol 2003; 3: 71–79.
66. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, NC3Rs Reporting Guidelines Working Group. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 2010; 160: 1577–1579. DOI: 10.1111/j.1476-5381.2010.00872.x